Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RAD52 | P43351 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12847436 | 0.86 | MAPT (0.39) | MAPTMAPK1SMN1; SMN2 | |
| SCHEMBL1403972 | 0.80 | — | — | |
| SCHEMBL27418812 | 0.80 | MAPT (0.35) | MAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL188592 | 0.80 | — | — | |
| SCHEMBL5715676 | 0.80 | MEN1 (0.32) | MEN1ALDH1A1KMT2A | |
| SCHEMBL9641416 | 0.79 | MEN1 (0.39) | MAPTMEN1ALDH1A1EGFRLMNA | |
| SCHEMBL23116984 | 0.78 | MAPT (0.33) | MAPTMAPK1NPSR1 | |
| SCHEMBL1404024 | 0.78 | MAPT (0.35) | MAPTMEN1ALDH1A1LMNAKMT2A | |
| SCHEMBL6382395 | 0.77 | MAPT (0.39) | MAPTMEN1ALDH1A1EGFRLMNA | |
| SCHEMBL24579002 | 0.77 | MAPT (0.39) | MAPTMEN1ALDH1A1EGFRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022125589-A1 | LIPIDOID COMPOSITIONS AND METHODS OF USE THEREOF | TRUSTEES OF TUFTS COLLEGE (US) | 2022-06-16 | — | — | WO | disclosed |
| US-20110052673-A1 | THERAPEUTIC COMPOSITIONS | SHIRE HUMAN GENETIC THERAPIES, INC. | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110052673-A1 | THERAPEUTIC COMPOSITIONS | PHOSPHO1, SGMS1, APOB | MAPT 513/4885MEN1 718/4885ALDH1A1 2111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.